Recent clinical trials have shown that moderate AD patients, with established brain amyloid and tau pathologies, do not benefit cognitively from current therapeutic approaches, although some trials have shown potential benefits in mild and early stage AD patients (7–11). Here, MAPT is linked to Alzheimer disease.